Activ Surgical has announced that Dr. Manish Chand, consultant colorectal surgeon at University College London, has joined the company’s advisory board. The Activ Surgical Advisory Board is comprised of the foremost experts spanning various areas of surgical specialty and is instrumental in advising the company on product strategy and development.
In addition to his roles at University College London and University College Hospital, Chand serves as a professor of surgery for Apollo Hospitals Group and chief medical officer at The AIS Channel.
Chand has been at the forefront of minimally invasive surgery for which he is recognized globally as a key opinion leader and has taught surgeons laparoscopy, Transanal Total Mesorectal Excision (TaTME) and robotic surgery in several regions across the world, according to a news release announcing the appointment.
“He is a respected clinical academic with research interests in fluorescence imaging, artificial intelligence (AI) and computer vision, and has been recently listed within the top 2% of scientists in his field based on standardized citation metrics,” the release states.
“Dr. Chand, a world-renowned surgeon and one of the leading voices in the field of colorectal surgery, is an impactful addition to Activ Surgical’s Advisory Board,” said Todd Usen, chief executive officer, Activ Surgical. “His work on minimally invasive approaches, including TaTME, coupled with the training he has received for robotic surgery, has been groundbreaking. His background and expertise will be relied on heavily by our leadership team as we identify new use cases and applications for our ActivInsights software suite during our commercial rollout in 2022.”
“I am delighted to join Activ Surgical’s Advisory Board and look forward to working with my fellow peers and colleagues alongside the company’s leadership team to improve surgical outcomes and reduce unintended medical errors in the OR,” said Chand. “The vision that Todd and his team have established for Activ Surgical is bold, innovative and potentially market changing. I am confident that the technology the company is developing will help democratize surgical care around the world.”